1
|
Clark KL, Park K, Lee C. Exploring the cause of reduced production responses to feeding corn dried distillers' grains in lactating dairy cows. J Dairy Sci 2024:S0022-0302(24)00752-5. [PMID: 38642660 DOI: 10.3168/jds.2023-24356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 03/10/2024] [Indexed: 04/22/2024]
Abstract
An experiment was conducted to identify the factors that cause reduced production of cows fed a diet with high corn distiller's grains with solubles (DDGS). We hypothesized that the factors could be high S content in DDGS which may directly (S toxicity) or indirectly [dietary cation-anion difference (DCAD)] cause reduced production. We also hypothesized that high polyunsaturated fatty acids (PUFA) in DDGS could be another major factor. In a randomized complete block design, 60 lactating cows (15 primiparous and 45 multiparious; average ± SD at the beginning of the trial: milk yield, 44.0 ± 6.9 kg/d; DIM, 123 ± 50; BW, 672 ± 82 kg) were blocked and cows in each block were randomly assigned to one of the following treatments: SBM [4.7% fatty acids (FA), 0.22% S, and 178 mEq/kg DM of DCAD], a diet containing soybean meal as the main protein source; DG, SBM replacing mainly soybean byproducts and supplemental fat with DG at 30% dietary DM (4.7% FA, 0.44% S, and 42 mEq/kg DM of DCAD); SBM+S, SBM with sodium bisulfate for additional dietary S (4.8% FA, 0.37% S, and 198 mEq/kg DM of DCAD); SBM+CO, SBM with corn oil (4.7% FA, 0.23%, and 165 mEq/kg DM of DCAD); and DG+DCAD, DG with increased DCAD (4.7% FA, 0.40% S, and 330 mEq/kg DM of DCAD). Due to the limited tie stalls, the blocks of 1 to 6 started the experiment first as phase 1 and the rest of the blocks as phase 2 started the experiment after phase 1. All cows were fed the SBM diet for 10 d as a covariate period followed by the experimental period for 35 d. Data were analyzed using the PROC MIXED of SAS, block and phase were random effects and treatments, repeated wk, and interaction were fixed effects. There was an interaction of wk by treatment for DMI. While milk yield did not change, milk fat concentration tended to decrease (2.78 vs. 3.34%) for DG compared with SBM. Dry matter, OM, NDF, and CP digestibilities were lower when cows were fed the DG diet compared with SBM. Additionally, cows fed DG had lower blood concentrations of HCO3-, base excess, and tCO2 compared with SBM. The SBM+S diet did not affect production, nutrient digestibility, or blood parameters when compared with SBM. The SBM+CO diet decreased milk fat concentration and yield compared with SBM. The DG+DCAD diet tended to increase milk fat yield and concentration (1.24 vs. 1.47 kg/d; 2.78 vs. 3.37%) and increased ECM (40.9 vs. 45.1 kg/d) compared with DG but did not improve nutrient digestibility. However, blood HCO3-, base excess, and tCO2 were greater for DG+DCAD compared with DG. In conclusion, the indirect role of S-, altering DCAD, along with the high PUFA content in DDGS appears to be the factors causing reduced production responses to a high DDGS diet. Increasing DCAD to 300 mEq/kg DM in a high DDGS diet can be a feeding strategy to alleviate the reduced production responses.
Collapse
Affiliation(s)
- K L Clark
- Department of Animal Sciences, The Ohio State University, Wooster, OH 44691
| | - K Park
- Department of Animal Sciences, The Ohio State University, Wooster, OH 44691
| | - C Lee
- Department of Animal Sciences, The Ohio State University, Wooster, OH 44691.
| |
Collapse
|
2
|
Larkin A, Kim JS, Kim N, Baek SH, Yamada S, Park K, Tai K, Yanagi Y, Park JH. Accuracy of artificial intelligence-assisted growth prediction in skeletal Class I preadolescent patients using serial lateral cephalograms for a 2-year growth interval. Orthod Craniofac Res 2024. [PMID: 38321788 DOI: 10.1111/ocr.12764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/23/2024] [Indexed: 02/08/2024]
Abstract
OBJECTIVE To investigate the accuracy of artificial intelligence-assisted growth prediction using a convolutional neural network (CNN) algorithm and longitudinal lateral cephalograms (Lat-cephs). MATERIALS AND METHODS A total of 198 Japanese preadolescent children, who had skeletal Class I malocclusion and whose Lat-cephs were available at age 8 years (T0) and 10 years (T1), were allocated into the training, validation, and test phases (n = 161, n = 17, n = 20). Orthodontists and the CNN model identified 28 hard-tissue landmarks (HTL) and 19 soft-tissue landmarks (STL). The mean prediction error values were defined as 'excellent,' 'very good,' 'good,' 'acceptable,' and 'unsatisfactory' (criteria: 0.5 mm, 1.0 mm, 1.5 mm, and 2.0 mm, respectively). The degree of accurate prediction percentage (APP) was defined as 'very high,' 'high,' 'medium,' and 'low' (criteria: 90%, 70%, and 50%, respectively) according to the percentage of subjects that showed the error range within 1.5 mm. RESULTS All HTLs showed acceptable-to-excellent mean PE values, while the STLs Pog', Gn', and Me' showed unsatisfactory values, and the rest showed good-to-acceptable values. Regarding the degree of APP, HTLs Ba, ramus posterior, Pm, Pog, B-point, Me, and mandibular first molar root apex exhibited low APPs. The STLs labrale superius, lower embrasure, lower lip, point of lower profile, B', Pog,' Gn' and Me' also exhibited low APPs. The remainder of HTLs and STLs showed medium-to-very high APPs. CONCLUSION Despite the possibility of using the CNN model to predict growth, further studies are needed to improve the prediction accuracy in HTLs and STLs of the chin area.
Collapse
Affiliation(s)
- A Larkin
- Postgraduate Orthodontic Program, Arizona School of Dentistry & Oral Health, A.T. Still University, Mesa, Arizona, USA
| | - J-S Kim
- Department of Biomedical Engineering, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - N Kim
- Department of Convergence Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - S-H Baek
- Department of Orthodontics, School of Dentistry, Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| | - S Yamada
- Department of Dental Informatics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - K Park
- Department of Biomedical Engineering, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - K Tai
- Postgraduate Orthodontic Program, Arizona School of Dentistry & Oral Health, A.T. Still University, Mesa, Arizona, USA
- Private Practice of Orthodontics, Okayama, Japan
| | - Y Yanagi
- Department of Dental Informatics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - J H Park
- Postgraduate Orthodontic Program, Arizona School of Dentistry & Oral Health, A.T. Still University, Mesa, Arizona, USA
- Graduate School of Dentistry, Kyung Hee University, Seoul, Republic of Korea
| |
Collapse
|
3
|
Shim H, Jang K, Bang YH, Chu HBK, Kang J, Lee JY, Cho S, Lee HS, Jeon J, Hwang T, Joe S, Lim J, Choi JH, Joo EH, Park K, Moon JH, Han KY, Hong Y, Lee WY, Kim HC, Yun SH, Cho YB, Park YA, Huh JW, Shin JK, Pyo DH, Hong H, Lee HO, Park WY, Yang JO, Kim YJ. Comprehensive profiling of DNA methylation in Korean patients with colorectal cancer. BMB Rep 2024; 57:110-115. [PMID: 37605617 PMCID: PMC10910091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 06/27/2023] [Accepted: 08/21/2023] [Indexed: 08/23/2023] Open
Abstract
Alterations in DNA methylation play an important pathophysiological role in the development and progression of colorectal cancer. We comprehensively profiled DNA methylation alterations in 165 Korean patients with colorectal cancer (CRC), and conducted an in-depth investigation of cancer-specific methylation patterns. Our analysis of the tumor samples revealed a significant presence of hypomethylated probes, primarily within the gene body regions; few hypermethylated sites were observed, which were mostly enriched in promoter-like and CpG island regions. The CpG Island Methylator PhenotypeHigh (CIMP-H) exhibited notable enrichment of microsatellite instability-high (MSI-H). Additionally, our findings indicated a significant correlation between methylation of the MLH1 gene and MSI-H status. Furthermore, we found that the CIMP-H had a higher tendency to affect the right-side of the colon tissues and was slightly more prevalent among older patients. Through our methylome profile analysis, we successfully verified the thylation patterns and clinical characteristics of Korean patients with CRC. This valuable dataset lays a strong foundation for exploring novel molecular insights and potential therapeutic targets for the treatment of CRC. [BMB Reports 2024; 57(2): 110-115].
Collapse
Affiliation(s)
- Hyeran Shim
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Kiwon Jang
- Korea Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea
| | - Yeong Hak Bang
- Department of Digital Health, Samsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University, Seoul 06355, Korea
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Hoang Bao Khanh Chu
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Jisun Kang
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Jin-Young Lee
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Sheehyun Cho
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Hong Seok Lee
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Jongbum Jeon
- Korea Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea
| | - Taeyeon Hwang
- Korea Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea
| | - Soobok Joe
- Korea Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea
| | - Jinyeong Lim
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06355, Korea
| | - Ji-Hye Choi
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06355, Korea
| | - Eun Hye Joo
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06355, Korea
| | - Kyunghee Park
- Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea, Seoul 04779, Korea
| | - Ji Hwan Moon
- Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea, Seoul 04779, Korea
| | - Kyung Yeon Han
- Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea, Seoul 04779, Korea
| | - Yourae Hong
- Department of Oncology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium, Seoul 04779, Korea
| | - Woo Yong Lee
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Hee Cheol Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Seong Hyeon Yun
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Yong Beom Cho
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Yoon Ah Park
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Jung Wook Huh
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Jung Kyong Shin
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Dae Hee Pyo
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Hyekyung Hong
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
| | - Hae-Ock Lee
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
- Department of Biomedicine and Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea
| | - Woong-Yang Park
- Department of Digital Health, Samsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University, Seoul 06355, Korea
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06355, Korea
- Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea, Seoul 04779, Korea
| | - Jin Ok Yang
- Korea Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea
| | - Young-Joon Kim
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
- LepiDyne Co., Ltd., Seoul 04779, Korea
| |
Collapse
|
4
|
Jara TC, Park K, Vahmani P, Van Eenennaam AL, Smith LR, Denicol AC. Stem cell-based strategies and challenges for production of cultivated meat. Nat Food 2023; 4:841-853. [PMID: 37845547 DOI: 10.1038/s43016-023-00857-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 09/05/2023] [Indexed: 10/18/2023]
Abstract
Cultivated meat scale-up and industrial production will require multiple stable cell lines from different species to recreate the organoleptic and nutritional properties of meat from livestock. In this Review, we explore the potential of stem cells to create the major cellular components of cultivated meat. By using developments in the fields of tissue engineering and biomedicine, we explore the advantages and disadvantages of strategies involving primary adult and pluripotent stem cells for generating cell sources that can be grown at scale. These myogenic, adipogenic or extracellular matrix-producing adult stem cells as well as embryonic or inducible pluripotent stem cells are discussed for their proliferative and differentiation capacity, necessary for cultivated meat. We examine the challenges for industrial scale-up, including differentiation and culture protocols, as well as genetic modification options for stem cell immortalization and controlled differentiation. Finally, we discuss stem cell-related safety and regulatory challenges for bringing cultivated meat to the marketplace.
Collapse
Affiliation(s)
- T C Jara
- Department of Animal Science, University of California Davis, Davis, CA, USA
| | - K Park
- Department of Animal Science, University of California Davis, Davis, CA, USA
| | - P Vahmani
- Department of Animal Science, University of California Davis, Davis, CA, USA
| | - A L Van Eenennaam
- Department of Animal Science, University of California Davis, Davis, CA, USA
| | - L R Smith
- Department of Neurobiology, Physiology and Behavior, University of California Davis, Davis, CA, USA.
| | - A C Denicol
- Department of Animal Science, University of California Davis, Davis, CA, USA
| |
Collapse
|
5
|
Chang SJ, Kim E, Kwon YO, Im H, Park K, Kim J, Jeong D, Kim D, Park JH. Benefits and harms of normal saline instillation before endotracheal suctioning in mechanically ventilated adult patients in intensive care units: A systematic literature review and meta-analysis. Intensive Crit Care Nurs 2023; 78:103477. [PMID: 37384975 DOI: 10.1016/j.iccn.2023.103477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 06/04/2023] [Accepted: 06/05/2023] [Indexed: 07/01/2023]
Abstract
OBJECTIVES This systematic review aimed to identify the effects of normal saline instillation before endotracheal suctioning on clinical outcomes in critically ill patients on a mechanical ventilator. RESEARCH METHODOLOGY This review was based on the guidelines of the National Evidence-based Healthcare Collaborating Agency in Korea and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Six electronic databases were searched for relevant literature. Other sources were also searched, including the reference lists of identified reports and previous systematic reviews. After the initial literature search, a two-step retrieval process was performed to select eligible studies. Then, data were collected using a newly developed form, and the risk of bias was assessed using the checklists of the Joanna Briggs Institute. Data were analyzed using both narrative syntheses and meta-analyses. RESULTS In total, 16 studies: 13 randomized controlled trials and three quasi-experimental studies, were included. From the narrative syntheses, instilling normal saline before endotracheal suctioning was associated with a decrease in oxygen saturation, prolonged time for oxygen saturation to recover to baseline, decreased arterial pH, increased secretion amount, reduced incidence of ventilator-associated pneumonia, increased heart rate, and increased systolic blood pressure. Meta-analyses showed a significant difference in heart rate at five minutes after suctioning but no significant differences in oxygen saturation at two and five minutes after suctioning and heart rate at two minutes after suctioning. CONCLUSION This systematic review indicated that instilling normal saline before performing endotracheal suctioning has more harmful effects than benefits. IMPLICATIONS FOR CLINICAL PRACTICE As recommended in the current guidelines, it is necessary to refrain from routine normal saline instillation before endotracheal suctioning.
Collapse
Affiliation(s)
- Sun Ju Chang
- College of Nursing & The Research Institute of Nursing Science, Seoul National University, Seoul, South Korea.
| | - Eunhye Kim
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea.
| | - Young Ok Kwon
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea.
| | - Hyomin Im
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea.
| | - Kyunghee Park
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea.
| | - Jina Kim
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea.
| | - Dawoon Jeong
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea
| | - Dain Kim
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea
| | - Ju Hee Park
- Department of Nursing, Seoul National University Hospital, Daehak-ro 103, Jongro-gu, Seoul 406-799, South Korea.
| |
Collapse
|
6
|
Zeze T, Shinjo T, Sato K, Nishimura Y, Imagawa M, Chen S, Ahmed AK, Iwashita M, Yamashita A, Fukuda T, Sanui T, Park K, King GL, Nishimura F. Endothelial Insulin Resistance Exacerbates Experimental Periodontitis. J Dent Res 2023; 102:1152-1161. [PMID: 37448347 DOI: 10.1177/00220345231181539] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/15/2023] Open
Abstract
Epidemiological studies suggest that the severity of periodontitis is higher in people with diabetes than in healthy individuals. Insulin resistance might play a crucial role in the pathogenesis of multiple diabetic complications and is reportedly induced in the gingiva of rodents with type 2 diabetes; however, the molecular mechanisms underlying the pathogenesis of diabetes-related periodontitis remain unclear. Therefore, we aimed to investigate whether endothelial insulin resistance in the gingiva may contribute to the pathogenesis of periodontitis as well as elucidate its underlying molecular mechanisms. We demonstrated that insulin treatment downregulated lipopolysaccharide (LPS)-induced or tumor necrosis factor α (TNFα)-induced VCAM1 expression in endothelial cells (ECs) via the PI3K/Akt activating pathway, resulting in reduced cellular adhesion between ECs and leukocytes. Hyperglycemia-induced selective insulin resistance in ECs diminished the effect of insulin on LPS- or TNFα-stimulated VCAM1 expression. Vascular endothelial cell-specific insulin receptor knockout (VEIRKO) mice exhibited selective inhibition of the PI3K/Akt pathway in the gingiva and advanced experimental periodontitis-induced alveolar bone loss via upregulation of Vcam1, Tnfα, Mcp-1, Rankl, and neutrophil migration into the gingiva compared with that in the wild-type (WT) mice despite being free from diabetes. We also observed that insulin-mediated activation of FoxO1, a downstream target of Akt, was suppressed in the gingiva of VEIRKO and high-fat diet (HFD)-fed mice, hyperglycemia-treated ECs, and primary ECs from VEIRKO. Further analysis using ECs transfected with intact and mutated FoxO1, with mutations at 3 insulin-mediated phosphorylation sites (T24A, S256D, S316A), suggested that insulin-mediated regulation of VCAM1 expression and cellular adhesion of ECs with leukocytes was attenuated by mutated FoxO1 overexpression. These results suggest that insulin resistance in ECs may contribute to the progression of periodontitis via dysregulated VCAM1 expression and cellular adhesion with leukocytes, resulting from reduced activation of the PI3K/Akt/FoxO1 axis.
Collapse
Affiliation(s)
- T Zeze
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - T Shinjo
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - K Sato
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - Y Nishimura
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - M Imagawa
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - S Chen
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - A-K Ahmed
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - M Iwashita
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - A Yamashita
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - T Fukuda
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - T Sanui
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - K Park
- Section of Vascular Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - G L King
- Section of Vascular Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - F Nishimura
- Section of Periodontology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| |
Collapse
|
7
|
Park K, Baek HJ. Contextual response to the COVID-19 pandemic from the experience of South Korea. Public Health 2023; 222:e7-e8. [PMID: 36045020 PMCID: PMC9339972 DOI: 10.1016/j.puhe.2022.07.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 07/19/2022] [Indexed: 12/04/2022]
Affiliation(s)
- K Park
- Gyeong-gi Infectious Disease Control Center, Suwon, Gyeonggi-do, Republic of Korea
| | - H J Baek
- Division of Rheumatology, Department of Internal Medicine, Gachon University College of Medicine, Gil Medical Center, Incheon, Republic of Korea.
| |
Collapse
|
8
|
Park YH, Im SA, Park K, Wen J, Lee KH, Choi YL, Lee WC, Min A, Bonato V, Park S, Ram S, Lee DW, Kim JY, Lee SK, Lee WW, Lee J, Kim M, Kim HS, Weinrich SL, Ryu HS, Kim TY, Dann S, Kim YJ, Fernandez DR, Koh J, Wang S, Park SY, Deng S, Powell E, Ravi RK, Bienkowska J, Rejto PA, Park WY, Kan Z. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. Genome Med 2023; 15:55. [PMID: 37475004 PMCID: PMC10360358 DOI: 10.1186/s13073-023-01201-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 06/05/2023] [Indexed: 07/22/2023] Open
Abstract
BACKGROUND Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2- MBC); however, resistance is common and poorly understood. A comprehensive genomic and transcriptomic analysis of pretreatment and post-treatment tumors from patients receiving palbociclib plus ET was performed to delineate molecular mechanisms of drug resistance. METHODS Tissue was collected from 89 patients with HR+/HER2- MBC, including those with recurrent and/or metastatic disease, receiving palbociclib plus an aromatase inhibitor or fulvestrant at Samsung Medical Center and Seoul National University Hospital from 2017 to 2020. Tumor biopsy and blood samples obtained at pretreatment, on-treatment (6 weeks and/or 12 weeks), and post-progression underwent RNA sequencing and whole-exome sequencing. Cox regression analysis was performed to identify the clinical and genomic variables associated with progression-free survival. RESULTS Novel markers associated with poor prognosis, including genomic scar features caused by homologous repair deficiency (HRD), estrogen response signatures, and four prognostic clusters with distinct molecular features were identified. Tumors with TP53 mutations co-occurring with a unique HRD-high cluster responded poorly to palbociclib plus ET. Comparisons of paired pre- and post-treatment samples revealed that tumors became enriched in APOBEC mutation signatures, and many switched to aggressive molecular subtypes with estrogen-independent characteristics. We identified frequent genomic alterations upon disease progression in RB1, ESR1, PTEN, and KMT2C. CONCLUSIONS We identified novel molecular features associated with poor prognosis and molecular mechanisms that could be targeted to overcome resistance to CKD4/6 plus ET. TRIAL REGISTRATION ClinicalTrials.gov, NCT03401359. The trial was posted on 18 January 2018 and registered prospectively.
Collapse
Affiliation(s)
- Yeon Hee Park
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
| | - Seock-Ah Im
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.
| | - Kyunghee Park
- Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea
| | - Ji Wen
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA
| | - Kyung-Hun Lee
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | - Yoon-La Choi
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea
| | - Won-Chul Lee
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA
| | - Ahrum Min
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | | | - Seri Park
- Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea
| | - Sripad Ram
- Drug Safety R&D, Pfizer Inc, San Diego, CA, USA
| | - Dae-Won Lee
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | - Ji-Yeon Kim
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Su Kyeong Lee
- Research Center for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea
| | - Won-Woo Lee
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | - Jisook Lee
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA
| | - Miso Kim
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | | | | | - Han Suk Ryu
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | - Tae Yong Kim
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | - Stephen Dann
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA
| | - Yu-Jin Kim
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | | | - Jiwon Koh
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | - Shuoguo Wang
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA
| | - Song Yi Park
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
| | | | - Eric Powell
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA
| | | | | | - Paul A Rejto
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA
| | - Woong-Yang Park
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea
- Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea
| | - Zhengyan Kan
- Oncology Research & Development, Pfizer Inc, San Diego, CA, USA.
| |
Collapse
|
9
|
Reed R, Park K, Waddell B, Timbers TA, Li C, Baxi K, Giacomin RM, Leroux MR, Carvalho CE. The Caenorhabditis elegans Shugoshin regulates TAC-1 in cilia. Sci Rep 2023; 13:9410. [PMID: 37296204 PMCID: PMC10256747 DOI: 10.1038/s41598-023-36430-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 06/03/2023] [Indexed: 06/12/2023] Open
Abstract
The conserved Shugoshin (SGO) protein family is essential for mediating proper chromosome segregation from yeast to humans but has also been implicated in diverse roles outside of the nucleus. SGO's roles include inhibiting incorrect spindle attachment in the kinetochore, regulating the spindle assembly checkpoint (SAC), and ensuring centriole cohesion in the centrosome, all functions that involve different microtubule scaffolding structures in the cell. In Caenorhabditis elegans, a species with holocentric chromosomes, SGO-1 is not required for cohesin protection or spindle attachment but appears important for licensing meiotic recombination. Here we provide the first functional evidence that in C. elegans, Shugoshin functions in another extranuclear, microtubule-based structure, the primary cilium. We identify the centrosomal and microtubule-regulating transforming acidic coiled-coil protein, TACC/TAC-1, which also localizes to the basal body, as an SGO-1 binding protein. Genetic analyses indicate that TAC-1 activity must be maintained below a threshold at the ciliary base for correct cilia function, and that SGO-1 likely participates in constraining TAC-1 to the basal body by influencing the function of the transition zone 'ciliary gate'. This research expands our understanding of cellular functions of Shugoshin proteins and contributes to the growing examples of overlap between kinetochore, centrosome and cilia proteomes.
Collapse
Affiliation(s)
- R Reed
- Department of Biology, University of Saskatchewan, Saskatoon, Canada
| | - K Park
- Department of Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada
- Centre for Cell Biology, Development, and Disease, Simon Fraser University, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada
- Terry Fox Laboratory, BC Cancer, Vancouver, BC, V5Z 1L3, Canada
- Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada
| | - B Waddell
- Department of Biology, University of Saskatchewan, Saskatoon, Canada
| | - T A Timbers
- Department of Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada
- Centre for Cell Biology, Development, and Disease, Simon Fraser University, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada
| | - C Li
- Department of Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada
- Centre for Cell Biology, Development, and Disease, Simon Fraser University, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada
| | - K Baxi
- Department of Biology, University of Saskatchewan, Saskatoon, Canada
| | - R M Giacomin
- Department of Biology, University of Saskatchewan, Saskatoon, Canada
| | - M R Leroux
- Department of Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
- Centre for Cell Biology, Development, and Disease, Simon Fraser University, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada.
| | - C E Carvalho
- Department of Biology, University of Saskatchewan, Saskatoon, Canada.
| |
Collapse
|
10
|
Kim JY, Park K, Park WY, Lee JE, Kim SW, Nam SJ, Lee SK, Park YH. Abstract P6-01-37: Tumor microenvironment subtype influence the response of neoadjuvant chemotherapy in breast cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p6-01-37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Introduction Recent transcriptome analysis developed a holistic tumor microenvironment (TME) classification platform based on immune and fibrotic markers. This TME classification had four categories, immune enriched, fibrotic (IE/F); immune enriched, non-fibrotic (IE); Fibrotic (F); and Immune Desert (D). And these four TME subtypes are a predictive biomarker to immunotherapy in multiple cancer and four subtypes have been changed during treatment. Previously our study suggested baseline immune features and dynamic immune response on-treatment were predictive of treatment outcome in BC with neoadjuvant chemotherapy (NAC). In this study, we evaluated the impact of TME classification and dynamic change of TME classification on treatment outcome in BC with NAC. Methods Early and locally advanced BCs which would be planned to receive standard NAC (four cycles of anthracycline plus cyclophosphamide and four cycles of docetaxel or docetaxel plus trastuzumab for human epidermal growth factor receptor 2[HER2+] disease or six cycles of docetaxel, carboplatin, trastuzumab and pertuzumab for HER2+ disease) followed by curative surgery. We prospectively collected tumor tissue and matched blood three times for each patients: at BC diagnosis (T1), three weeks after the first cycle of NAC (T2), and curative surgery (T3). RNASeq was performed to classify TME subtype. In terms of clinical variables, clinical stage and IHC subtype at diagnosis, pathologic complete response (pCR), distant recurrence free survival (DRFS) and overall survival (OS) were used. Generalized logistic regression was used for predicting RCB class and pCR with clinical and genomic characteristics at T1. Kaplan-Meier analysis were performed to analysis DRFS and OS. Results In total, 210 patients who were treated with scheduled NAC were enrolled. Finally, RNASeq in 240 BC tissues (T1:119, T2:91 and T3:30) were conducted from 142 patients. In 119 BCs which was performed RNASeq at T1, hormone receptor(HR)+, HER2- BC was 32 (26.9%), 29 of HR+HER2+ BC (24.4%), 18 of HR-HER2+ BC (15.1%) and 44 of triple negative BC (TNBC) (37.0%). In TME classification, immune desert (D) was most frequently observed (45.3%), followed by IE (35.3%), F (10.1%) and IE/F (9.2%). The association between BC subtype and TME subtype suggested that HR+HER2- BC was frequently categorized into D (22 of 32, 68.8%) whereas TNBC was into IE (24 of 44, 54.5%) (p< 0.001). TME subtype has been dynamically changed during NAC. At T2, IE subtype was most frequently observed (27.5%) followed by D (25.3%), IE/F (24.2%) and F (23.1%). The inclination of TME change were different according to NAC response. In BC achieved pCR, IE/F subtype had increased (4 at T1 and 10 at T2) and decrease of D subtype (15 at T1 and 3 at T2). In BC with non-pCR, IE/F subtype had slightly increased at T2 (7 at T1 and 12 at T2) but there was no IE/F subtype at T3 point. Contrarily, D subtype had decreased at T2 but increased at T3 (39 at T1, 20 at T2 and 24 at T3). The impact of TME subtype was different according to pCR status. In BC with pCR, F subtype had poor prognosis in DRFS and OS compared to other subtype ([5year DRFS rate for F vs. others: 66.7% vs. 93.2%, p=0.028], [5year OS rate for F vs. others: 70.7% vs. 100%, p< 0.001]). In BC without pCR, there was no different DRFS and OS according to TME subtypes. Conclusion Our data suggested that TME subtype has been changed during NAC and the subtype switching was affected by the NAC response. Moreover, TME subtype may have prognostic role in DRFS and OS according to pCR status.
Citation Format: ji-Yeon Kim, Kyunghee Park, woong-Yang Park, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Yeon Hee Park. Tumor microenvironment subtype influence the response of neoadjuvant chemotherapy in breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-01-37.
Collapse
Affiliation(s)
| | | | | | | | - Seok Won Kim
- 5Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - Seok Jin Nam
- 6Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - Se Kyung Lee
- 7Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | | |
Collapse
|
11
|
Kim Y, Park K, Kim YJ, Shin SW, Kim YJ, Choi C, Noh JM. Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model. Int J Mol Sci 2022; 23:ijms232415539. [PMID: 36555180 PMCID: PMC9779092 DOI: 10.3390/ijms232415539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 11/17/2022] [Accepted: 12/05/2022] [Indexed: 12/13/2022] Open
Abstract
Although the combination of radiotherapy and immunotherapy has proven to be effective in lung cancer treatment, it may not be sufficient to fully activate the antitumor immune response. Here, we investigated whether entinostat, a histone deacetylase inhibitor, could improve the efficacy of radiotherapy and anti-PD-1 in a murine syngeneic LL/2 tumor model. A total of 12 Gy of X-rays administered in two fractions significantly delayed tumor growth in mice, which was further enhanced by oral entinostat administration. Flow cytometry-aided immune cell profiling revealed that entinostat increased radiation-induced infiltration of myeloid-derived suppressor cells and CD8+ T cells with decreased regulatory T-cells (Tregs). Transcriptomics-based immune phenotype prediction showed that entinostat potentiated radiation-activated pathways, such as JAK/STAT3/interferon-gamma (IFN-γ) and PD-1/PD-L1 signaling. Entinostat augmented the antitumor efficacy of radiation and anti-PD-1, which may be related to an increase in IFN-γ-producing CD8+ T-cells with a decrease in Treg cells. Comparative transcriptomic profiling predicted that entinostat increased the number of dendritic cells, B cells, and T cells in tumors treated with radiation and anti-PD-1 by inducing MHC-II genes. In conclusion, our findings provided insights into how entinostat improves the efficacy of ionizing radiation plus anti-PD-1 therapy and offered clues for developing new strategies for clinical trials.
Collapse
Affiliation(s)
- Yeeun Kim
- Department of Radiation Oncology, Samsung Medical Center, Seoul 06351, Republic of Korea
| | - Kyunghee Park
- Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Republic of Korea
| | - Yeon Jeong Kim
- Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Republic of Korea
| | - Sung-Won Shin
- Department of Radiation Oncology, Samsung Medical Center, Seoul 06351, Republic of Korea
| | - Yeon Joo Kim
- Department of Radiation Oncology, Samsung Medical Center, Seoul 06351, Republic of Korea
| | - Changhoon Choi
- Department of Radiation Oncology, Samsung Medical Center, Seoul 06351, Republic of Korea
- Correspondence: (C.C.); (J.M.N.)
| | - Jae Myoung Noh
- Department of Radiation Oncology, Samsung Medical Center, Seoul 06351, Republic of Korea
- Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
- Correspondence: (C.C.); (J.M.N.)
| |
Collapse
|
12
|
Maurer C, Galmarini S, Solazzo E, Kuśmierczyk-Michulec J, Baré J, Kalinowski M, Schoeppner M, Bourgouin P, Crawford A, Stein A, Chai T, Ngan F, Malo A, Seibert P, Axelsson A, Ringbom A, Britton R, Davies A, Goodwin M, Eslinger PW, Bowyer TW, Glascoe LG, Lucas DD, Cicchi S, Vogt P, Kijima Y, Furuno A, Long PK, Orr B, Wain A, Park K, Suh KS, Quérel A, Saunier O, Quélo D. Third international challenge to model the medium- to long-range transport of radioxenon to four Comprehensive Nuclear-Test-Ban Treaty monitoring stations. J Environ Radioact 2022; 255:106968. [PMID: 36148707 DOI: 10.1016/j.jenvrad.2022.106968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 07/08/2022] [Accepted: 07/15/2022] [Indexed: 06/16/2023]
Abstract
In 2015 and 2016, atmospheric transport modeling challenges were conducted in the context of the Comprehensive Nuclear-Test-Ban Treaty (CTBT) verification, however, with a more limited scope with respect to emission inventories, simulation period and number of relevant samples (i.e., those above the Minimum Detectable Concentration (MDC)) involved. Therefore, a more comprehensive atmospheric transport modeling challenge was organized in 2019. Stack release data of Xe-133 were provided by the Institut National des Radioéléments/IRE (Belgium) and the Canadian Nuclear Laboratories/CNL (Canada) and accounted for in the simulations over a three (mandatory) or six (optional) months period. Best estimate emissions of additional facilities (radiopharmaceutical production and nuclear research facilities, commercial reactors or relevant research reactors) of the Northern Hemisphere were included as well. Model results were compared with observed atmospheric activity concentrations at four International Monitoring System (IMS) stations located in Europe and North America with overall considerable influence of IRE and/or CNL emissions for evaluation of the participants' runs. Participants were prompted to work with controlled and harmonized model set-ups to make runs more comparable, but also to increase diversity. It was found that using the stack emissions of IRE and CNL with daily resolution does not lead to better results than disaggregating annual emissions of these two facilities taken from the literature if an overall score for all stations covering all valid observed samples is considered. A moderate benefit of roughly 10% is visible in statistical scores for samples influenced by IRE and/or CNL to at least 50% and there can be considerable benefit for individual samples. Effects of transport errors, not properly characterized remaining emitters and long IMS sampling times (12-24 h) undoubtedly are in contrast to and reduce the benefit of high-quality IRE and CNL stack data. Complementary best estimates for remaining emitters push the scores up by 18% compared to just considering IRE and CNL emissions alone. Despite the efforts undertaken the full multi-model ensemble built is highly redundant. An ensemble based on a few arbitrary runs is sufficient to model the Xe-133 background at the stations investigated. The effective ensemble size is below five. An optimized ensemble at each station has on average slightly higher skill compared to the full ensemble. However, the improvement (maximum of 20% and minimum of 3% in RMSE) in skill is likely being too small for being exploited for an independent period.
Collapse
Affiliation(s)
- C Maurer
- Zentralanstalt für Meteorologie und Geodynamik (ZAMG), Vienna, Austria.
| | - S Galmarini
- European Commission - Joint Research Center (JRC), Ispra VA, Italy
| | - E Solazzo
- European Commission - Joint Research Center (JRC), Ispra VA, Italy
| | | | - J Baré
- Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO), Vienna, Austria
| | - M Kalinowski
- Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO), Vienna, Austria
| | - M Schoeppner
- Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO), Vienna, Austria
| | - P Bourgouin
- Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO), Vienna, Austria
| | - A Crawford
- National Oceanic and Atmospheric Administration Air Resources Laboratory (NOAA-ARL), College Park, MD, USA
| | - A Stein
- National Oceanic and Atmospheric Administration Air Resources Laboratory (NOAA-ARL), College Park, MD, USA
| | - T Chai
- National Oceanic and Atmospheric Administration Air Resources Laboratory (NOAA-ARL), College Park, MD, USA
| | - F Ngan
- National Oceanic and Atmospheric Administration Air Resources Laboratory (NOAA-ARL), College Park, MD, USA
| | - A Malo
- Environment and Climate Change Canada (ECCC), Meteorological Service of Canada, Canadian Meteorological Centre (CMC), Environmental Emergency Response Section, RSMC Montréal, Dorval, Québec, Canada
| | - P Seibert
- University of Natural Resources and Life Sciences (BOKU), Institute of Meteorology and Climatology, Vienna, Austria
| | - A Axelsson
- Swedish Defence Research Agency (FOI), Stockholm, Sweden
| | - A Ringbom
- Swedish Defence Research Agency (FOI), Stockholm, Sweden
| | - R Britton
- Atomic Weapons Establishment/United Kingdom-National Data Center (AWE/UK-NDC), Aldermaston, Reading, United Kingdom
| | - A Davies
- Atomic Weapons Establishment/United Kingdom-National Data Center (AWE/UK-NDC), Aldermaston, Reading, United Kingdom
| | - M Goodwin
- Atomic Weapons Establishment/United Kingdom-National Data Center (AWE/UK-NDC), Aldermaston, Reading, United Kingdom
| | - P W Eslinger
- Pacific Northwest National Laboratory (PNNL), Richland, WA, USA
| | - T W Bowyer
- Pacific Northwest National Laboratory (PNNL), Richland, WA, USA
| | - L G Glascoe
- National Atmospheric Release Advisory Center (NARAC) at the Lawrence Livermore National Laboratory (LLNL), Livermore, CA, USA
| | - D D Lucas
- National Atmospheric Release Advisory Center (NARAC) at the Lawrence Livermore National Laboratory (LLNL), Livermore, CA, USA
| | - S Cicchi
- National Atmospheric Release Advisory Center (NARAC) at the Lawrence Livermore National Laboratory (LLNL), Livermore, CA, USA
| | - P Vogt
- National Atmospheric Release Advisory Center (NARAC) at the Lawrence Livermore National Laboratory (LLNL), Livermore, CA, USA
| | - Y Kijima
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki, Japan
| | - A Furuno
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki, Japan
| | - P K Long
- Vietnam Atomic Energy Institute (VINATOM), Hanoi, Vietnam
| | - B Orr
- Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), Yallambie/Miranda, Australia
| | - A Wain
- Bureau of Meteorology (BOM), Melbourne, Australia
| | - K Park
- Korea Atomic Energy Research Institute (KAERI), Daejeon, Republic of Korea
| | - K-S Suh
- Korea Atomic Energy Research Institute (KAERI), Daejeon, Republic of Korea
| | - A Quérel
- French Institute for Radiation Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France
| | - O Saunier
- French Institute for Radiation Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France
| | - D Quélo
- French Institute for Radiation Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France
| |
Collapse
|
13
|
Ghaderpour A, Jeong J, Kim Y, Zou Y, Park K, Hong E, Koh Y, Seong S. 335 HY209, a GPCR19 agonist, ameliorates atopic dermatitis in mice. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
14
|
Kim JJ, Oh S, Jung K, Oh S, Hong Y, Park K. 460P The role of fluorescence-based cell-free DNA assay for detection of cancer by comparing patients with and without cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
15
|
Park K, Yeich A, Craig T. AN UNUSUAL PRESENTATION OF STEVENS-JOHNSON SYNDROME (SJS) IN A PATIENT WITH TWO PRIOR SJS EPISODES. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
16
|
Watts A, Park K, Vohra S, Raj K, Toquica CC, Jalal A, Shah M, Patel KV. Inequalities in accessing quality healthcare, does insurance play a role? retrospective analysis of aortic emergencies from national inpatient sample 2019. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Aortic emergencies, dissection and rupture, are rare but catastrophic entities, with the cornerstone to survival being prompt diagnosis and treatment. Insurance status often limits access to healthcare, and our study aims to determine if it plays a role in the outcomes of aortic emergencies.
Method
A retrospective analysis of the 2019 Nationwide Inpatient Sample was conducted to identify hospitalization (Age ≥18 & non-elective) with aortic dissection and ruptured aortic aneurysms using ICD-10 codes. Discharge-level weight analysis was used to produce a national estimate. Variables were screened with univariate regression, and intermediate and co-linear variables were screened-out before a multivariable regression analysis model was built and performed to calculate the odds ratio.
Results
A total of 19,685 (0.06%) hospitalizations are identified for aortic emergencies (14965 dissections & 4720 ruptured aneurysms). The mean age was 58.56, 62.7% were males, and ethnic distribution was 65.1% white, 19.5% blacks, 7.6% Hispanics, and others.
11.4% of the hospitalizations underwent diagnostic imaging with either CTA/MRA/TEE/Aortography within 24 hours. Hypotension/shock was present in 32% of these hospitalizations and was a risk factor for mortality OR 3.21 (p<0.00), increasing LOS by an average of 5.1 days and resource utilization by 156,000$. Another risk factor for mortality was stroke/TIA (OR-1.76, p<0.00), increasing LOS and resource utilization by 3.1 days and 80,662$, respectively.
3220 hospitalizations (16.4%) did not survive the course, and the mortality rate in uninsured, Medicare, and Medicaid was 17%, 20%,9% compared with 12% in privately insured. On crude analysis, uninsured and medicare patients appeared to have higher odds of mortality [OR 1.50, p<0.04, and OR 1.83 p-value <0.002 respectively], however upon adjusting for confounders, only uninsured patients showed statistically significant difference (OR 2.13, p<0.002). Similar results were corroborated on analyzing hospitalizations for aortic dissection; however, insurance status did not influence mortality in a ruptured aneurysm.
When comparing hospitalization of median household income of ≥79,000$ with household of median income of 59,000–78,999 $, 46,000–58,999 $ and <46,000$ had higher odds of mortality (OR-1.38, p<0.04), (OR-1.44, p<0.02) and (OR-1.44, p<0.03) respectively. Of all the insurance types, a statistically significant difference compared with private insurance, Medicaid on average, had 2.8 more days and incurred an additional 62,912$ in resource utilization (p<0.00).
Conclusion
Inequalities in accessing healthcare, median household income, and insurance status are risk factors for mortality in aortic emergencies. Efforts are needed to bridge the gap in this particular facet of social determinants of health to find a sustainable and equitable solution for quality healthcare for aall regardless of their insurance status.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Watts
- Saint Peter's University Hospital , New Brunswick , United States of America
| | - K Park
- Memorial Healthcare System, Internal Medicine , Pembroke Pines , United States of America
| | - S Vohra
- Saint Peter's University Hospital , New Brunswick , United States of America
| | - K Raj
- Saint Peter's University Hospital , New Brunswick , United States of America
| | - C C Toquica
- Saint Peter's University Hospital , New Brunswick , United States of America
| | - A Jalal
- Memorial Healthcare System, Internal Medicine , Pembroke Pines , United States of America
| | - M Shah
- Saint Peter's University Hospital , New Brunswick , United States of America
| | - K V Patel
- Saint Peter's University Hospital , New Brunswick , United States of America
| |
Collapse
|
17
|
Kang S, Ryu B, Sa J, Kim H, Park K, Yu S, Hong D, Kim K. P12.04.A Exosomes from glioma associated sphere forming cells induce a transition of invasive phenotype via transfer of EMP2 and CA9. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Glioblastoma multiforme (GBM) mostly occurs local recurrence at normal parenchyme adjacent tumor despite of conventional treatment. Glioma stem like cells (GSC) forming intratumoral heterogeneity within the GBM acquired the microenvironmental adaptation by inter-exosomal contents exchange between heterogenic cells. In addition, GSC has an invasive potential as like human GBM. Therefore, we investigate whether exosomal proteins of GSC affect the normal tissue invasion in GBM.
Material and Methods
Exosomes were isolated by Size-Exclusion method from conditioned media and validated by Electron microscope and Immunoblot assay. Exosomal proteomics were examined with Liquid Chromatography-Mass Spectrometry (LC/MS). To produce the fluorescent exosome, bi-cistron vectors were cloned with shRNA and CD63-GFP. To identify the effect of tranfected exosome, the isolated exosomes were treated to recipient cells and examined the invasion by 3D invasion assay and mouse intracranial model.
Results
Firstly, we dichotomized two groups following tumor invasion at matrigel assay and GSC derived orthotopic mouse model. CSC2 and X01 GSCs revealed highly invasive phenotype whereas 83NS and 528NS GSCs did not. Exosome was isolated in each group and identified by CD63 expression or electron microscopy. In proteomics analysis, hypoxia, extracellular matrix organization, GTPase cycle related proteins were enriched in highly invasive cell’s exosome. Among them, we focused the carbonic anhydrase IX (CA9) and the epithelial membrane protein 2 (EMP2) on its permissive role to glioblastoma invasion respectively. CA9 and EMP2 mRNA and protein levels were verified in GSCs and their exosomes and the high expression levels were detected in CSC2 and X01 compared to the low one in 83NS and 528NS GSCs. To evaluate the effects of CA9 and EMP2 on exosome mediated invasion potential, viral bi-cistron vectors was composed with the target gene knockdown and the CD63 fluorescence was used to detect intracellular exosome transfer. Interestingly, the decreased expression of phosphorylated FAK, a key invasive marker, was observed after Lentiviral mediated CA9- and EMP2-knockdown in highly invasive CSC2. To identify whether CA9 and EMP2 proteins are the intracellular effector protein responsible for exosome mediated glioma invasion, the donor exosomes (Exo-CSC2-sh-CA9 and Exo-CSC2-EMP2, after Lentiviral transfection to CSC2s) were isolated and treated to the non invasive 528NS cells as recipient cells. In 3D invasion assay, Exo-CSC2-shCA9 or Exo-CSC2-shEMP2 mediated tumor invasion was significantly decreased at 528NS GSCs compared to Exo-CSC2-shEV. These features were found at mouse intracranial model as well.
Conclusion
Together with these, we conclude that exosome derived from GSCs induces a transition of invasive phenotype via transfer of EMP2 and CA9 proteins.
Collapse
Affiliation(s)
- S Kang
- Department of Neurosurgery, Korea University Anam Hospital , Seoul , Korea, Republic of
| | - B Ryu
- Department of Neurosurgery, Korea University Anam Hospital , Seoul , Korea, Republic of
| | - J Sa
- Biomedical Sciences, Korea University College of Medicine , Seoul , Korea, Republic of
| | - H Kim
- Department of Neurosurgery, Korea University Anam Hospital , Seoul , Korea, Republic of
| | - K Park
- Department of Neurosurgery, Korea University Anam Hospital , Seoul , Korea, Republic of
| | - S Yu
- Department of Neurosurgery, Korea University Anam Hospital , Seoul , Korea, Republic of
| | - D Hong
- Department of Neurosurgery, Korea University Anam Hospital , Seoul , Korea, Republic of
| | - K Kim
- Department of Applied Chemistry, Kyung Hee University , Seoul , Korea, Republic of
| |
Collapse
|
18
|
Kim Y, Lee M, Park K, Choi Y. P13-09 Subacute inhalation toxicity study of 2-chlorotoluene in rats. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
19
|
Reck M, Barlesi F, Yang JH, Westeel V, Felip E, Özgüroğlu M, Dols MC, Sullivan R, Kowalski D, Andric Z, Lee D, Sezer A, Shamrai V, Szalai Z, Wang X, Xiong H, Jacob N, Mehr KT, Park K. OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Maharjan A, Acharya M, Lee D, C PK, Kusma S, Adhikari M, Lee J, Kim J, Kim M, Park K, Park H, Hwang S, Kim C, Kim H, Heo Y. P13-06 Comparison of overall immunity levels among workers at grape or pear orchards, rose greenhouse, and open-field onion farms. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
21
|
Park K, Jeon Y, Bae C, Lee E. EP02.03-013 Should Visceral Pleural Invasion Be Prognostic Factor in Early-Stage Lung Adenocarcinoma With Tumor Size 3cm or Less? J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Park K, Hong H, Gwon S. Enhanced thermoelectric properties of Li and Mg co−substituted Bi2Sr2Co2O fabricated by combined conventional sintering and spark plasma sintering. INORG CHEM COMMUN 2022. [DOI: 10.1016/j.inoche.2022.110005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Park K, Nam J, Lee H, Kim T, Ryu H, Ki Y, Kim JJ, Oh S, Oh S, Hong Y. 1745P Phase II study of neoadjuvant chemotherapy with 4 cycles of dose dense MVAC followed by radical surgery in Korean patients with MIBC and locally advanced urothelial carcinoma of bladder (NCT04047693). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
24
|
Georges F, Rashad MNH, Stefanko A, Dlamini M, Karki B, Ali SF, Lin PJ, Ko HS, Israel N, Adikaram D, Ahmed Z, Albataineh H, Aljawrneh B, Allada K, Allison S, Alsalmi S, Androic D, Aniol K, Annand J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Biswas D, Brash E, Bulumulla D, Campbell J, Camsonne A, Carmignotto M, Castellano J, Chen C, Chen JP, Chetry T, Christy ME, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, De Persio F, Deconinck W, Defurne M, Desnault C, Di D, Duer M, Duran B, Ent R, Fanelli C, Franklin G, Fuchey E, Gal C, Gaskell D, Gautam T, Glamazdin O, Gnanvo K, Gray VM, Gu C, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde CE, Ibrahim H, Jen CM, Jin K, Jones M, Kabir A, Keppel C, Khachatryan V, King PM, Li S, Li WB, Liu J, Liu H, Liyanage A, Magee J, Malace S, Mammei J, Markowitz P, McClellan E, Mazouz M, Meddi F, Meekins D, Mesik K, Michaels R, Mkrtchyan A, Montgomery R, Muñoz Camacho C, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obretch OF, Ou L, Palatchi C, Pandey B, Park S, Park K, Peng C, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Reimer PE, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Schmookler B, Shabestari MH, Shahinyan A, Sirca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Su T, Subedi A, Sulkosky V, Sun A, Thorne L, Tian Y, Ton N, Tortorici F, Trotta R, Urciuoli GM, Voutier E, Waidyawansa B, Wang Y, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye Z, Yero C, Zhang J, Zhao Y, Zhu P. Deeply Virtual Compton Scattering Cross Section at High Bjorken x_{B}. Phys Rev Lett 2022; 128:252002. [PMID: 35802440 DOI: 10.1103/physrevlett.128.252002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 03/28/2022] [Accepted: 04/18/2022] [Indexed: 06/15/2023]
Abstract
We report high-precision measurements of the deeply virtual Compton scattering (DVCS) cross section at high values of the Bjorken variable x_{B}. DVCS is sensitive to the generalized parton distributions of the nucleon, which provide a three-dimensional description of its internal constituents. Using the exact analytic expression of the DVCS cross section for all possible polarization states of the initial and final electron and nucleon, and final state photon, we present the first experimental extraction of all four helicity-conserving Compton form factors (CFFs) of the nucleon as a function of x_{B}, while systematically including helicity flip amplitudes. In particular, the high accuracy of the present data demonstrates sensitivity to some very poorly known CFFs.
Collapse
Affiliation(s)
- F Georges
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S F Ali
- Catholic University of America, Washington, DC 20064, USA
| | - P-J Lin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - H-S Ko
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826 Seoul, Korea
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - H Albataineh
- Texas A&M University-Kingsville, Kingsville, Texas 78363, USA
| | - B Aljawrneh
- North Carolina Agricultural and Technical State University, Greensboro, North Carolina 27411, USA
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Dipartimento di Fisica delle Università degli di Catania, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Campbell
- Dalhousie University, Nova Scotia, NS B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellano
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv-Yafo 6997801, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina Agricultural and Technical State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - F De Persio
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - W Deconinck
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Duer
- Tel Aviv University, Tel Aviv-Yafo 6997801, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Franklin
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - V M Gray
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Longwood University, Farmville, Virginia 23901, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - C E Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo 121613, Egypt
| | - C-M Jen
- Virginia Polytechnic Institute & State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W B Li
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - J Liu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - A Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - J Magee
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Mazouz
- Faculté des Sciences de Monastir, Monastir 5019, Tunisia
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesik
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - C Muñoz Camacho
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - O F Obretch
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Sirca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tian
- Shandong University, Jinan 250100, China
| | - N Ton
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Dipartimento di Fisica delle Università degli di Catania, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - E Voutier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Wang
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, Tunxi, Daizhen Road 245041, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z Ye
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
25
|
Park K, Yuk H, Yang M, Cho J, Lee H, Kim J. A biomimetic elastomeric robot skin using electrical impedance and acoustic tomography for tactile sensing. Sci Robot 2022; 7:eabm7187. [PMID: 35675452 DOI: 10.1126/scirobotics.abm7187] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Human skin perceives physical stimuli applied to the body and mitigates the risk of physical interaction through its soft and resilient mechanical properties. Social robots would benefit from whole-body robotic skin (or tactile sensors) resembling human skin in realizing a safe, intuitive, and contact-rich human-robot interaction. However, existing soft tactile sensors show several drawbacks (complex structure, poor scalability, and fragility), which limit their application in whole-body robotic skin. Here, we introduce biomimetic robotic skin based on hydrogel-elastomer hybrids and tomographic imaging. The developed skin consists of a tough hydrogel and a silicone elastomer forming a skin-inspired multilayer structure, achieving sufficient softness and resilience for protection. The sensor structure can also be easily repaired with adhesives even after severe damage (incision). For multimodal tactile sensation, electrodes and microphones are deployed in the sensor structure to measure local resistance changes and vibration due to touch. The ionic hydrogel layer is deformed owing to an external force, and the resulting local conductivity changes are measured via electrodes. The microphones also detect the vibration generated from touch to determine the location and type of dynamic tactile stimuli. The measurement data are then converted into multimodal tactile information through tomographic imaging and deep neural networks. We further implement a sensorized cosmetic prosthesis, demonstrating that our design could be used to implement deformable or complex-shaped robotic skin.
Collapse
Affiliation(s)
- K Park
- Department of Mechanical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| | - H Yuk
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - M Yang
- Department of Mechanical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| | - J Cho
- Department of Mechanical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| | - H Lee
- Institute of Smart Sensors, University of Stuttgart, Stuttgart, Germany
| | - J Kim
- Department of Mechanical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| |
Collapse
|
26
|
Park K, Byeon J, Yang Y, Cho H. Healthcare utilisation for elderly people at the onset of the COVID-19 pandemic in South Korea. BMC Geriatr 2022; 22:395. [PMID: 35524173 PMCID: PMC9072758 DOI: 10.1186/s12877-022-03085-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Accepted: 04/25/2022] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND At the onset of the coronavirus disease 2019 (COVID-19) pandemic, health care systems were severely disrupted in many countries and in particular, elderly people vulnerable to COVID-19 may have been reluctant to receive their medical treatment. METHODS We conducted interrupted time series analyses (ITSA) using nationwide medical claim data between January 2020 and July 2020, with focus on different disease categories for the patients of 65 to 84-year-olds, i.e., acute upper respiratory infections (AURIs) vs. chronic diseases. RESULTS AURIs and chronic diseases showed a sharp contrast with respect to the change in healthcare service utilisation. First, the utilisation rate for chronic diseases changed little whereas for AURIs it dropped by 20.4% year-over-year (yoy) at the onset of the pandemic (week 6, 2020). Second, as social distancing relaxed (week 17, 2020), the AURIs patients trended up and even reached to 7.8% above yoy whereas no significant change found for chronic diseases. CONCLUSIONS The uninterrupted treatment for chronic diseases in contrast to the AURIs implies that the governmental and public responses to the pandemic outbreak worked for efficient healthcare provision to patients in needs of regular check-ups and treatment in the middle of an infectious disease crisis.
Collapse
Affiliation(s)
- K. Park
- Health Insurance Research Institute, National Health Insurance Service, Wonju, 26464 South Korea
| | - J. Byeon
- Health Insurance Research Institute, National Health Insurance Service, Wonju, 26464 South Korea
| | - Y. Yang
- Health Insurance Research Institute, National Health Insurance Service, Wonju, 26464 South Korea
| | - H. Cho
- Health Insurance Research Institute, National Health Insurance Service, Wonju, 26464 South Korea
| |
Collapse
|
27
|
Park I, Keam B, Kim M, Yoon S, Lee J, Park K, Seo J. W120 Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Park K, Park J, You E, Kim H, Park C, Kim Y. M051 The variant call format normalization is essential for the accuracy of variant nomenclature. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Girard N, Park K, Viteri S, Schioppa C, Diels J, Oguz M, Rodrigues B, Rahhali N, Sermon J, Ghilotti F, Li T, Knoblauch R, Mahadevia P, Cho B. 19P Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
30
|
Lee S, Park K, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park WY, Im SA, Park YH. Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast 2022; 62:52-60. [PMID: 35124320 PMCID: PMC8819475 DOI: 10.1016/j.breast.2022.01.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 01/23/2022] [Accepted: 01/24/2022] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Palbociclib plus endocrine therapy (ET) demonstrated significant progression-free survival (PFS) benefit in Young Pearl, a randomized phase ll trial comparing palbociclib + ET versus capecitabine in premenopausal women with hormone receptor positive, HER2 negative metastatic breast cancer (MBC). This exploratory analysis investigated potential biomarkers of palbociclib plus ET on PFS. PATIENTS AND METHODS Of 178 patients randomized (92 palbociclib plus ET; 86 capecitabine), we performed targeted sequencing (141 patients) and whole transcriptome sequencing (165 patients) using baseline tumor samples to examine genomic alteration in relation to drug response on PFS. Hazard ratios (HRs) were estimated using unstratified Cox proportional hazards models. RESULTS PIK3CA (41%) and TP53 (33%) mutations and CCND1 copy number variation (29%) were found most frequently in targeted sequencing of 141 patients. ESR1 mutations were found only in 3.5% of patients of this population. Luminal type showed better prognosis in palbociclib + ET arm but no impact on PFS difference in capecitabine arm. High TMB, TP53 mutation, PTEN loss of function mutation and RB1 pathway alteration showed worse prognosis in palbociclib plus ET arm. Patients with BRCA2 pathogenic mutations showed worse prognosis regardless of PAM50 subtypes. AURKA mutation/amplification, BRIP1/MYC/RAD51C amplification were significantly associated to the patients with short PFS <6 month. CONCLUSION Of palbociclib plus ET, luminal type showed better prognosis and BRCA2 pathogenic mutation showed worse prognosis regardless luminal/non-luminal type. Further exploration of molecular variables is warranted to determine and validate biomarkers of efficacy and resistance.
Collapse
Affiliation(s)
- Soohyeon Lee
- Division of Oncology-Hematology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea
| | - Kyunghee Park
- Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea
| | - Gun Min Kim
- Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
| | - Kyung Hae Jung
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Seok Yun Kang
- Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, South Korea
| | - In Hae Park
- Department of Medical Oncology, Korea University College of Medicine, Korea University Guro Hospital, Seoul, South Korea
| | - Jee Hyun Kim
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea
| | - Hee Kyung Ahn
- Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea
| | - Woong-Yang Park
- Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea
| | - Seock-Ah Im
- Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, South Korea.
| | - Yeon Hee Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
| |
Collapse
|
31
|
Rodriguez Abreu D, Reck M, Şendur N, Park K, Lee D, Cicin I, Yumuk P, Orlandi F, Leal T, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B, Hsia TC, Otterson G, Woods T, Jensen E, Samkari A, Boyer M. 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
32
|
Trigo J, Cho B, Park K, Girard N, Viteri S, Garrido P, Krebs M, Thayu M, Knoblauch R, Xie J, Bauml J, Schnepp R, Londhe A, Mahadevia P, Leighl N. 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
33
|
Drilon A, Subbiah V, Gautschi O, Tomasini P, De Braud F, Solomon B, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker S, Puri T, Lin A, Loong H, Besse B. 27P Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.036] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
34
|
Christy ME, Gautam T, Ou L, Schmookler B, Wang Y, Adikaram D, Ahmed Z, Albataineh H, Ali SF, Aljawrneh B, Allada K, Allison SL, Alsalmi S, Androic D, Aniol K, Annand J, Arrington J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Bhatt H, Bhetuwal D, Biswas D, Brash E, Bulumulla D, Camacho CM, Campbell J, Camsonne A, Carmignotto M, Castellanos J, Chen C, Chen JP, Chetry T, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, Deconinck W, Defurne M, Desnault C, Di D, Dlamini M, Duer M, Duran B, Ent R, Fanelli C, Fuchey E, Gal C, Gaskell D, Georges F, Gilad S, Glamazdin O, Gnanvo K, Gramolin AV, Gray VM, Gu C, Habarakada A, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Hernandez AV, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde C, Ibrahim H, Israel N, Jen CM, Jin K, Jones M, Kabir A, Karki B, Keppel C, Khachatryan V, King PM, Li S, Li W, Liu H, Liu J, Liyanage AH, Mack D, Magee J, Malace S, Mammei J, Markowitz P, Mayilyan S, McClellan E, Meddi F, Meekins D, Mesick K, Michaels R, Mkrtchyan A, Moffit B, Montgomery R, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obrecht RF, Ohanyan K, Palatchi C, Pandey B, Park K, Park S, Peng C, Persio FD, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Rashad MNH, Reimer PE, Riordan S, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Shabestari MH, Shahinyan A, Širca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Stefanko A, Su T, Subedi A, Sulkosky V, Sun A, Tan Y, Thorne L, Ton N, Tortorici F, Trotta R, Uniyal R, Urciuoli GM, Voutier E, Waidyawansa B, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye ZH, Yero C, Zhang J, Zhao YX, Zhu P. Form Factors and Two-Photon Exchange in High-Energy Elastic Electron-Proton Scattering. Phys Rev Lett 2022; 128:102002. [PMID: 35333083 DOI: 10.1103/physrevlett.128.102002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 11/06/2021] [Accepted: 01/31/2022] [Indexed: 06/14/2023]
Abstract
We present new precision measurements of the elastic electron-proton scattering cross section for momentum transfer (Q^{2}) up to 15.75 (GeV/c)^{2}. Combined with existing data, these provide an improved extraction of the proton magnetic form factor at high Q^{2} and double the range over which a longitudinal or transverse separation of the cross section can be performed. The difference between our results and polarization data agrees with that observed at lower Q^{2} and attributed to hard two-photon exchange (TPE) effects, extending to 8 (GeV/c)^{2} the range of Q^{2} for which a discrepancy is established at >95% confidence. We use the discrepancy to quantify the size of TPE contributions needed to explain the cross section at high Q^{2}.
Collapse
Affiliation(s)
- M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Y Wang
- William and Mary, Williamsburg, Virginia 23185, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 77843, USA
| | - S F Ali
- Catholic University of America, Washington, District of Columbia 20064, USA
| | - B Aljawrneh
- North Carolina A&T State University, Greensboro, North Carolina 27411, USA
- Al Zaytoonah University of Jordan, Amman 11733, Jordan
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S L Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000, Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - J Arrington
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- William and Mary, Williamsburg, Virginia 23185, USA
| | | | - X Bai
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Department of Physics and Astronomy, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C M Camacho
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - J Campbell
- Dalhousie University, Nova Scotia NS B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv-Yafo 69978, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- William and Mary, Williamsburg, Virginia 23185, USA
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina A&T State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - W Deconinck
- William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - M Duer
- Tel Aviv University, Tel Aviv-Yafo 69978, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Georges
- Ecole Centrale Paris, 3 Rue Joliot Curie, 91190 Gif-sur-Yvette, France
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A V Gramolin
- Boston University, Boston, Massachusetts 02215, USA
| | - V M Gray
- William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A V Hernandez
- Catholic University of America, Washington, DC 20064, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Randolph Macon College, Ashland, Virginia 23005, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo, 12613, Egypt
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - C-M Jen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - J Liu
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A H Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - D Mack
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Magee
- William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - S Mayilyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesick
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - B Moffit
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R F Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - K Ohanyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - F D Persio
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Stony Brook, State University of New York, New York 11794, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Širca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tan
- Shandong University, Shandong, Jinan 250100, China
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - N Ton
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Department of Physics and Astronomy, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, Pittsburgh, Pennsylvania 15282, USA
| | - R Uniyal
- Catholic University of America, Washington, DC 20064, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - E Voutier
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, 44 Daizhen Road, Tunxi District, Huangshan, Anhui Province, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z H Ye
- University of Virginia, Charlottesville, Virginia 232904, USA
- Tsinghua University, 30 Shuangqing Rd, Haidian District, Beijing 100190, China
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - Y X Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
35
|
Kim JY, Park K, Park WY, Lee JE, Kim SW, Nam SJ, Yu J, Im YH, Ahn JS, Park YH. Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p3-13-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neutrotrophin receptor tyrosine kinase (NTRK) gene fusions (NTRK1, NTRK2, or NTRK3) are oncogenic drivers of various tumor types. The NTRK fusion was detected in less than 5% of breast, colorectal, lung or any other types of cancers. However, large scaled next generation sequencing data for NTRK fusion in breast cancer have not existed. In this study, we performed RNASeq and fusion analysis including NTRK genes. Methods: We prospectively collected BC tumor tissues from the translational research conducted in Samsung Medical Center. Fusion was predicted from RNAseq using the following seven softwares(SWs): ChimeraScan, DeFuse, MapSplice, TophatFusion, STAR.Arriba, STAR.fusion, and STAR.SEQR. To remove false-positive fusion calls, calls less than 3 left/right spanning reads and 10 total supporting reads were removed. After filtering out the blacklist fusion calls which were recurrently detected, calls commonly predicted in more than two SWs were analyzed. Results: In total 629 BC samples, 613 samples were finally analyzed after quality control (QC) of RNASeq. According to immunohistochemistry (IHC) profile, 356(58.7%) was hormone receptor (HR) positive human epidermal growth factor receptor 2 (HER2) negative BC, 42 (6.9%) of HR positive HER2 positive BC, 53 (8.7%) of HR negative, HER2 positive and 155(25.6%) of triple negative BC (TNBC). PAM50 prediction informed that 174(28.9%) of luminal A, 151(24.6%) of luminal B, 170 (27.7%) of basal-like, 85 (13.9%) of HER2-enriched and 33 (5.4%) of normal. In median number of fusion events, 12 was called by ChimeraScan (Interquartile range [IQR]: 5, 33), 57 by DeFuse (IQR: 33, 82), eight by Mapsplice (IQR: 5, 12), two by TophatFusion (IQR: 0, 4), five by STAR.Arriba (IQR: 2, 12), two by STAR.fusion (IQR:0, 5) and three by STAR.SEQR fusion caller (IQR: 1, 7) after call filtering. After initial fusion call, we excluded the results from ChimeraScan and DeFuse fusion callers because of discrepancy of number of called fusion events. In five fusion callers, median number of fusion events was eight (IQR :2,20) per BC sample. In terms of NTRK fusion, we detected NTRK2-BANCR fusion event in one TNBC patients (1/425, 0.2%). This fusion was detected in four of five SWs for fusion detection with significant number of supporting reads in RNASeq. NTRK2-BANCR fusion was the out-of-frame fusion, which C-terminal truncated protein kinase domain of NTRK2 and its partner long non-coding RNA BANCR was combined and RNA expression of this fusion was increased. Other fusion events of BCs were NCOR2-PARP4 (3.7%), BRD4-NWD1 (3.7%), ESR1-RGS17 (1.8%), FGFR1-TACC1 (0.2%) and MKRN1-BRAF (0.2%). In BC subtype according to IHC, fusion events were more frequently observed in TNBC compared with other subtypes regardless of the type of fusion filters. In terms of intrinsic subtype, fusion events were most frequently observed in basal like type and least in normal like intrinsic subtype (all ps<0.05, respectively). Conclusions: In this large scaled RNASeq data analysis, a few fusion events were observed in BC patients. Prevalence of NTRK was extremely rare. Additional investigation including functional validation would be followed.
Citation Format: Ji-Yeon Kim, Kyunghee Park, Woong-Yang Park, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jonghan Yu, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park. Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-13-08.
Collapse
Affiliation(s)
- Ji-Yeon Kim
- Samsung Medical Center, Seoul, Korea, Republic of
| | | | | | | | - Seok Won Kim
- Samsung Medical Center, Seoul, Korea, Republic of
| | - Seok Jin Nam
- Samsung Medical Center, Seoul, Korea, Republic of
| | - Jonghan Yu
- Samsung Medical Center, Seoul, Korea, Republic of
| | | | - Jin Seok Ahn
- Samsung Medical Center, Seoul, Korea, Republic of
| | | |
Collapse
|
36
|
Kim JY, Park K, Park WY, Lee JE, Kim SW, Nam SJ, Lee SK, Kan Z, Park YH. Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p1-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The advance of next generation sequencing (NGS) leads to give the abundant genetic information of breast cancer (BC). We developed the prediction model of neoadjuvant chemotherapy (NAC) response and long term survival using genetic characteristics in cooperation with clinicpathologic features. Methods: Early and locally advanced BCs which would be planned to receive standard NAC (four cycles of anthracycline plus cyclophosphamide and four cycles of docetaxel or docetaxel plus trastuzumab for human epidermal growth factor receptor 2[HER2+] disease) followed by curative surgery. We prospectively collected tumor tissue and matched blood three times for each patients: at BC diagnosis (T1), three weeks after the first cycle of NAC (T2), and curative surgery (T3). Whole exome sequencing (WES) and RNASeq were performed to detect somatic mutation, mutational signature, tumor mutational burden (TMB) and PAM50 prediction was to classify intrinsic subtype. In terms of clinical variables, clinical stage and IHC subtype at diagnosis, pathologic complete response (pCR), residual cancer burden (RCB) class and distant recurrence free survival (DRFS) were used for prediction model development. Logistic regression was used for predicting RCB class and pCR with clinical and genomic variables at T1. Univariate and multivariate Cox regression were performed to identify prognostic factors for DRFS. Results: In total, 210 patients who were treated with scheduled NAC were enrolled. Finally, WES in 252 BC tissues (T1:123, T2:106 and T3:23) RNASeq in 198 BC tissues (T1:100, T2:77 and T3:21) were conducted from 123 patients. In NAC response, 52 patients achieved pCR(42.3%) and 14 patients were in RCB class 3, 39 in class 2, 14 in class 1 and 51 in class 0. Median follow up duration was 44months and distant recurrence was observed in 13 patients. TP53 mutation (60%) was the most commonly detected genetic alteration followed by TTN(31%), ERBB2(25%) and PIK3CA(18%). Eight BCL11A (3%) and 3 MPL mutations (1%) were also observed respectively. Serial tumor sequencing suggested that mutation profile have not changed during NAC. In terms of mutational signature, signature 3 was most frequently observed and no difference was observed in serial sequencing data. In addition, APOBEC (sig.2) and HRD (sig.3) were observed differently according to intrinsic subtype. In terms of intrinsic subtype, basal subtype decreased during NAC and luminal A type increased. Median TMB was 87 (range, 14-570). In prediction model, clinical N3(cN3) stage (Odds ratio [OR] of cN3 vs. not : 4.536, 95% confidence interval [CI]: 0.925, 44.016, p=0.042) and intrinsic subtype at BC diagnosis (OR of non-luminal vs. luminal types: 0.208, 95% CI: 0.062, 0.604, p=0.001) were associated with pCR. Clinical stage (OR of clinical stage III vs. II: 4.115, 95% CI: 1.094, 19.217, p=0.021), TMB (OR of TMB high vs. low: 0.255, 95% CI: 0.043,1.042, p.value=0.045), MPL genetic alteration (OR of mutation vs. wild type: 16.347, 95% CI: 0.797,1013.88, p.value=0.037), BCL11A (OR of mutation vs. wild type: 16.347, 95% CI: 0.797,1013.88, p.value=0.037) were associated with RCB class (3 vs. others). In terms of DRFS, prediction model consisted of clinical stage (Hazard ratio [HR] of stage III vs. II: 3.496, 95% confidence interval [CI]:1.337, 5.654), PIK3CA (HR of mutation vs. wild type: 1.572, 95% CI:-0.008, 3.152) TMB (HR of high vs. low: -1.999. 95% CI:-3.669, -0.329) had c-index of 0.861(95% CI:0.805, 0.916). Conclusions: During NAC, somatic mutation and mutation signature were consistently maintained while intrinsic subtype dynamically changed. In prediction model, TMB, PIK3CA mutation and clinical stage showed predictive roles on DRFS of BC in NAC setting.
Citation Format: Ji-Yeon Kim, Kyunghee Park, Woong-Yang Park, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Zhengyan Kan, Yeon Hee Park. Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-07.
Collapse
Affiliation(s)
- Ji-Yeon Kim
- Samsung Medical Center, Seoul, Korea, Republic of
| | | | | | | | - Seok Won Kim
- Samsung Medical Center, Seoul, Korea, Republic of
| | - Seok Jin Nam
- Samsung Medical Center, Seoul, Korea, Republic of
| | - Se Kyung Lee
- Samsung Medical Center, Seoul, Korea, Republic of
| | - Zhengyan Kan
- Oncology Research & Development, Pfizer, San Diego, CA
| | | |
Collapse
|
37
|
Kan Z, Im SA, Park K, Wen J, Lee KH, Choi YL, Lee WC, Min A, Bonato V, Park S, Ram S, Lee DW, Kim JY, Lee SK, Lee WW, Lee J, Kim M, Weinrich SL, Ryu HS, Kim TY, Dann S, Fernandez D, Koh J, Park SY, Deng S, Powell E, Ravi RK, Bienkowska J, Rejto PA, Park WY, Park YH. Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-pd2-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CDK4/6 inhibitors such as palbociclib in combination with endocrine therapy (ET) have remarkablyimproved the outcome of patients with ER+/HER2- metastatic breast cancer (MBC). However, manypatients are intrinsically resistant to CDK4/6i therapy, and those who respond eventually acquireresistance. Although high baseline CCNE1 expression and rare alterations in RB1 and FAT1 geneshave been shown to be associated with CDK4/6i resistance, the molecular mechanisms of CDK4/6iresistance are complex and remain poorly understood. To better understand and overcome CDK4/6iresistance, we performed multi-omics profiling of paired tumor biopsies from ER+/HER2- MBCpatients treated with palbociclib combined with ET. Tumor biopsies taken at pre-treatment, on-treatment, and progressive disease (PD) from 71 patients were profiled using whole-exomesequencing (WES), whole-transcriptome sequencing (RNA-Seq) and IHC analysis. Ourcomprehensive analysis identified several tumor intrinsic molecular markers associated with worsePFS, including the Luminal B subtype (p=0.012, HR=2.593), BRCA1/2 pathogenic mutation (p=0.012,HR=2.67) and mutation signatures linked to APOBEC enzymatic activity (p=0.002, HR=3.19).Conversely, the estrogen response signature (p=0.006, HR=0.43) was associated with favorableprognosis. Unsupervised analysis revealed a cluster of tumors enriched in homologousrecombination deficiency (HRD) linked genomic scars that was associated with poor prognosis(p=0.005, HR=2.49). Of note, these HRD-high tumors responded even more poorly to treatment whenco-occurring with TP53 somatic mutations. Integrative analysis further identified three poorprognosis clusters (IC2-4) enriched in Luminal B, proliferative and HRD features when compared tothe favorable prognosis cluster (IC1).Comparing baseline vs. PD samples, we observed a pattern of post-treatment enrichment for the poorprognosis markers. In addition, breast cancer-associated genes such as BRCA1/2, TP53 and PTENharbored a higher prevalence of genomic alterations including somatic mutation, amplification,. deletion and gene fusion at PD. Cell cycle gene expression and signatures also markedly increased atPD compared to baseline whereas estrogen response signatures decreased. Upon diseaseprogression, tumors had frequently switched to molecular subtypes with aggressive and estrogenindependent characteristics, demonstrating high plasticity in response to CDK4/6i and ET treatment.These patterns of acquired resistance were validated by IHC analysis of cyclins E1 and E2, Ki67 andpRb. To investigate the genomic alterations responsible for acquired resistance, we compared 21paired baseline and PD samples. We observed that PD-specific RB1 loss-of-function events occurredwith higher prevalence than previously reported, underscoring a major role of cell cycle de-regulation in conferring resistance to CDK4/6 inhibition. In this prospective longitudinal multi-omicsstudy, we identified novel candidate biomarkers that can be used to improve prediction of responseto CDK4/6i. In addition, we derived new insights into the molecular mechanisms of drug resistanceto palbociclib plus ET that will help guide therapeutic strategies and drug development inHR+/HER2− MBC.
Citation Format: Zhengyan Kan, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Scott L. Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Diane Fernandez, Jiwon Koh, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A. Rejto, Woong-Yang Park, Yeon Hee Park. Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD2-08.
Collapse
Affiliation(s)
| | - Seock-Ah Im
- Seoul National University Hospital, Seoul, Korea, Republic of
| | | | | | - Kyung-Hun Lee
- Seoul National University Hospital, Seoul, Korea, Republic of
| | - Yoon-La Choi
- Samsung Medical Center, Seoul, Korea, Republic of
| | | | - Ahrum Min
- Seoul National University Hospital, Seoul, Korea, Republic of
| | | | - Seri Park
- Sungkyunkwan University, Seoul, Korea, Republic of
| | | | - Dae-Won Lee
- Seoul National University Hospital, Seoul, Korea, Republic of
| | - Ji-Yeon Kim
- Samsung Medical Center, Seoul, Korea, Republic of
| | | | - Won-Woo Lee
- Seoul National University Hospital, Seoul, Korea, Republic of
| | | | - Miso Kim
- Seoul National University Hospital, Seoul, Korea, Republic of
| | | | - Han Suk Ryu
- Seoul National University Hospital, Seoul, Korea, Republic of
| | - Tae Yong Kim
- Seoul National University Hospital, Seoul, Korea, Republic of
| | | | | | - Jiwon Koh
- Seoul National University Hospital, Seoul, Korea, Republic of
| | - Song Yi Park
- Seoul National University Hospital, Seoul, Korea, Republic of
| | | | | | | | | | | | - Woong-Yang Park
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea, Republic of
| | | |
Collapse
|
38
|
Park S, Sun JM, Choi YL, Oh D, Kim H, Lee T, Chi S, Lee SH, Choi Y, Jung SH, Ahn MJ, Ahn Y, Park K, Shim Y. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. ESMO Open 2022; 7:100385. [PMID: 35158205 PMCID: PMC8850741 DOI: 10.1016/j.esmoop.2022.100385] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 12/23/2021] [Accepted: 12/26/2021] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND We evaluated the efficacy of adjuvant durvalumab after neoadjuvant concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS This randomized, double-blind, phase II study included patients with ESCC who underwent curative surgery after neoadjuvant CCRT. Patients were randomized to receive either durvalumab (20 mg/kg/i.v. every 4 weeks for 12 months) or placebo in a 1:1 ratio and were stratified by age and pathologic tumor stage. The primary endpoint was disease-free survival (DFS). RESULTS Between March 2016 and June 2018, 86 patients were randomized to the durvalumab (n = 45) or placebo (n = 41) arm. The median follow-up duration was 38.7 months. There was no difference in DFS [hazard ratio (HR) 1.18, 95% confidence interval (CI) 0.62-2.27, P = 0.61] or overall survival (HR 1.08, 95% CI 0.52-2.24, P = 0.85) between the two arms. Subgroup analysis was performed for patients for whom the post-CCRT programmed death-ligand 1 (PD-L1) expression profile could be assessed (n = 54). In the PD-L1-positive group, based on tumor proportion score ≥1%, durvalumab was associated with longer overall survival compared with the placebo (36-month survival rate: 94% versus 64%; HR 0.42, 95% CI 0.10-1.76), while in the PD-L1-negative group, it was associated with shorter overall survival (42% versus 55%; HR 1.53, 95% CI 0.48-4.83), showing the tendency of interaction between post-CCRT PD-L1 status and adjuvant durvalumab therapy for overall survival (interaction P = 0.18). CONCLUSIONS We failed to demonstrate that adjuvant durvalumab improved survival after neoadjuvant CCRT in patients with ESCC. However, post-CCRT PD-L1 expression could predict the survival of patients who receive adjuvant durvalumab after neoadjuvant CCRT, which needs to be validated.
Collapse
Affiliation(s)
- S. Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - J.-M. Sun
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea,Correspondence to: Dr Jong-Mu Sun, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea. Tel: +82-2-3410-1795
| | - Y.-L. Choi
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - D. Oh
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - H.K. Kim
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - T. Lee
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - S.A. Chi
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea
| | - S.-H. Lee
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Y.S. Choi
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - S.-H. Jung
- Department of Biostatistics and Bioinformatics, Duke University, Durham, USA
| | - M.-J. Ahn
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Y.C. Ahn
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - K. Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Y.M. Shim
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| |
Collapse
|
39
|
Park K, Belnap C. M165 RECURRENT NOCARDIOSIS IN A PATIENT WITH HYPOGAMMAGLOBULINEMIA SECONDARY TO MEMBRANOUS NEPHROPATHY. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Dlamini M, Karki B, Ali SF, Lin PJ, Georges F, Ko HS, Israel N, Rashad MNH, Stefanko A, Adikaram D, Ahmed Z, Albataineh H, Aljawrneh B, Allada K, Allison S, Alsalmi S, Androic D, Aniol K, Annand J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Biswas D, Brash E, Bulumulla D, Campbell J, Camsonne A, Carmignotto M, Castellano J, Chen C, Chen JP, Chetry T, Christy ME, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, De Persio F, Deconinck W, Defurne M, Desnault C, Di D, Duer M, Duran B, Ent R, Fanelli C, Franklin G, Fuchey E, Gal C, Gaskell D, Gautam T, Glamazdin O, Gnanvo K, Gray VM, Gu C, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde C, Ibrahim H, Jen CM, Jin K, Jones M, Kabir A, Keppel C, Khachatryan V, King PM, Li S, Li W, Liu J, Liu H, Liyanage A, Magee J, Malace S, Mammei J, Markowitz P, McClellan E, Meddi F, Meekins D, Mesik K, Michaels R, Mkrtchyan A, Montgomery R, Muñoz Camacho C, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obretch OF, Ou L, Palatchi C, Pandey B, Park S, Park K, Peng C, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Reimer PE, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Schmookler B, Shabestari MH, Shahinyan A, Sirca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Su T, Subedi A, Sulkosky V, Sun A, Thorne L, Tian Y, Ton N, Tortorici F, Trotta R, Urciuoli GM, Voutier E, Waidyawansa B, Wang Y, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye Z, Yero C, Zhang J, Zhao Y, Zhu P. Deep Exclusive Electroproduction of π^{0} at High Q^{2} in the Quark Valence Regime. Phys Rev Lett 2021; 127:152301. [PMID: 34678020 DOI: 10.1103/physrevlett.127.152301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 06/07/2021] [Accepted: 08/17/2021] [Indexed: 06/13/2023]
Abstract
We report measurements of the exclusive neutral pion electroproduction cross section off protons at large values of x_{B} (0.36, 0.48, and 0.60) and Q^{2} (3.1 to 8.4 GeV^{2}) obtained from Jefferson Lab Hall A experiment E12-06-014. The corresponding structure functions dσ_{T}/dt+εdσ_{L}/dt, dσ_{TT}/dt, dσ_{LT}/dt, and dσ_{LT^{'}}/dt are extracted as a function of the proton momentum transfer t-t_{min}. The results suggest the amplitude for transversely polarized virtual photons continues to dominate the cross section throughout this kinematic range. The data are well described by calculations based on transversity generalized parton distributions coupled to a helicity flip distribution amplitude of the pion, thus providing a unique way to probe the structure of the nucleon.
Collapse
Affiliation(s)
- M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S F Ali
- Catholic University of America, Washington, DC 20064, USA
| | - P-J Lin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - F Georges
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - H-S Ko
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826 Seoul, Korea
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Albataineh
- Texas A&M University-Kingsville, Kingsville, Texas 78363, USA
| | - B Aljawrneh
- North Carolina Ag. and Tech. State University, Greensboro, North Carolina 27411, USA
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Dipt. Di Fisica delle Uni. di Catania, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Campbell
- Dalhousie University, Nova Scotia B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellano
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv 699780 1, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina Ag. and Tech. State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - F De Persio
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - W Deconinck
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Duer
- Tel Aviv University, Tel Aviv 699780 1, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Franklin
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - V M Gray
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Randolph Macon College, Ashlan, Virginia 23005, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo 121613, Egypt
| | - C-M Jen
- Virginia Polytechnic Institute & State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - J Liu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - A Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - J Magee
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesik
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - C Muñoz Camacho
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - O F Obretch
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Sirca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tian
- Shandong University, Jinan, Shandong, 250100, China
| | - N Ton
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Dipt. Di Fisica delle Uni. di Catania, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - E Voutier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Wang
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, Huangshan, Anhui, 245041, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z Ye
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
41
|
Park S, Jung H, Cho J, Sun J, Lee S, Choi Y, Ahn J, Kim J, Park K, Zo J, Shim Y, Kim H, Ahn M. P15.01 Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Lee J, Park S, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. MA13.03 Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Jung H, Kim M, Kim J, Choi Y, Cho J, Park J, Park K, Park S, Sun J, Lee S, Ahn J, Park K, Ahn M. MA04.03 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17-21). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Nagasaka M, Goto K, Gomez J, Hida T, Shu C, Lee C, Park K, Cho B, Lee J, Ou S, Bestvina C, Natale R, Haddish-Berhane N, Bhattacharya A, Verheijen R, Agrawal T, Knoblauch R, Govindan R. P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Leighl N, Shu C, Minchom A, Felip E, Cousin S, Cho B, Park K, Han JY, Boyer M, Lee C, Garcia VM, Tomasini P, Viteri S, Xie J, Mertz J, Artis E, Schnepp R, Knoblauch R, Thayu M, Perez JT. 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1797] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
46
|
Park K, Quick V, Worobey J, Byrd-Bredbenner C. Associations of Recalled Weight-Based Teasing During Childhood with Eating Behaviors and Psychological Characteristics Among Mothers with Young Children. J Acad Nutr Diet 2021. [DOI: 10.1016/j.jand.2021.06.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
47
|
Lee E, Chung H, Lee Y, Lee EJ, Park Y, Kim Y, Park J, Ahn S, Kim J, Ahn K, Park K, Son W, Yeom D, Jung J, Won J, Oh S. 544P A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
48
|
Kim SB, Keam B, Shin SH, Chae Y, Seo S, Park K, Kim T, Park L, Hong SB, Ahn MJ. 887P Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
49
|
Shu C, Goto K, Ohe Y, Besse B, Park K, Wang Y, Griesinger F, Yang JH, Felip E, Sanborn R, Caro RB, Bauml J, Chen J, Fennema E, Mahoney J, Trani L, Knoblauch R, Thayu M, Cho B. 1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1798] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
50
|
Park K, Sabari J, Haura E, Shu C, Spira A, Salgia R, Reckamp K, Sanborn R, Govindan R, Bauml J, Curtin J, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch R, Cho B. 1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1852] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|